Patents by Inventor Fouad KANDEEL

Fouad KANDEEL has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR G-PROTEIN-COUPLED RECEPTOR 44 DETECTION
    Publication number: 20240002376
    Abstract: Disclosed herein, inter alia, are compounds and methods for G-protein-coupled receptor 44 detection.
    Type: Application
    Filed: August 23, 2021
    Publication date: January 4, 2024
    Inventors: Fouad Kandeel, Junfeng Li, Jiangling Peng
  • COMPOSITION AND METHODS FOR 3D CULTURE OF ISLET CELLS
    Publication number: 20230407265
    Abstract: Provided herein, inter alia, are compositions and methods for culturing islet cells.
    Type: Application
    Filed: May 18, 2023
    Publication date: December 21, 2023
    Inventors: Keiko OMORI, Fouad KANDEEL, Meirigeng QI
  • PROGRAMMING OF REGULATORY T CELLS BY EXTRACELLULAR VESICLES
    Publication number: 20230346939
    Abstract: Provided herein, inter alia, are compositions and methods for reprogramming immune cells for treating or preventing immune disorders. The methods include contacting immune cells with antigens, and administering the resultant immune cells to a subject who has an immune disorder.
    Type: Application
    Filed: September 15, 2021
    Publication date: November 2, 2023
    Inventor: Fouad Kandeel
  • EX VIVO EXPANSION OF REGULATORY T CELLS FOR SUPPRESSION OF GRAFT VERSUS HOST DISEASE
    Publication number: 20230346936
    Abstract: Provided herein, inter alia, are methods and compositions for treating or preventing graft-versus-host disease. The methods include administering to a tissue transplant recipient a composition comprising a donor-derived regulatory T cell.
    Type: Application
    Filed: September 15, 2021
    Publication date: November 2, 2023
    Inventor: Fouad Kandeel
  • PERSONALIZED TREATMENT USING METABOLIC FINGERPRINT BASED SIMULATION
    Publication number: 20230307107
    Abstract: Providing a personalized treatment by using a metabolic fingerprint is described. In one aspect, health information regarding a patient can be received and used to generate a metabolic fingerprint of that patient and using the metabolic fingerprint, characteristics of the glucose of the patient can be determined and used to generate a drug therapy plan to aid in the regulation of glucose within the patient. Additionally, using a patient's characteristics, a safe cardiopulmonary fitness of a patient can be determined.
    Type: Application
    Filed: June 4, 2021
    Publication date: September 28, 2023
    Applicant: CITY OF HOPE
    Inventors: Fouad KANDEEL, Christopher ORR
  • METHODS, COMPOSITIONS, AND KITS FOR IMPROVING PANCREATIC BETA CELL VIABILITY AND TREATING DISEASES OR CONDITIONS RELATED TO BETA CELL DESTRUCTION
    Publication number: 20210308189
    Abstract: The present disclosure provides novel methods for increasing ?-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase ?-cell viability.
    Type: Application
    Filed: April 19, 2021
    Publication date: October 7, 2021
    Applicant: CITY OF HOPE
    Inventors: Sanjay AWASTHI, Sushma YADAV, Ismail AL ABDULLAH, Fouad KANDEEL, Brian MCFADDEN, Indu NAIR, Sharad S. SINGHAL
  • Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction
    Patent number: 10980840
    Abstract: The present disclosure provides novel methods for increasing ?-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase ?-cell viability.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: April 20, 2021
    Assignee: CITY OF HOPE
    Inventors: Sanjay Awasthi, Sushma Yadav, Ismail Al Abdullah, Fouad Kandeel, Brian McFadden, Indu Nair, Sharad S. Singhal
  • METHODS, COMPOSITIONS, AND KITS FOR IMPROVING PANCREATIC BETA CELL VIABILITY AND TREATING DISEASES OR CONDITIONS RELATED TO BETA CELL DESTRUCTION
    Publication number: 20190015456
    Abstract: The present disclosure provides novel methods for increasing ?-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase ?-cell viability.
    Type: Application
    Filed: May 23, 2018
    Publication date: January 17, 2019
    Inventors: Sanjay AWASTHI, Sushma YADAV, Ismail AL ABDULLAH, Fouad KANDEEL, Brian MCFADDEN, Indu NAIR, Sharad S. SINGHAL
  • ULTRA-HIGH SENSITIVE MONITORING OF EARLY TRANSPLANTATION FAILURE
    Publication number: 20190010550
    Abstract: The present invention provides a method for detecting transplantation failure of a transplanted organ or cells which comprises detecting a donor-positive but recipient-negative DNA marker in the recipient's plasma using pyrophosphorolysis activated polymerization. Because of the high sensitivity, specificity and selectivity of pyrophosphorolysis activated polymerization, transplantation failure can be detected at early stages and treatment can be initiate earlier.
    Type: Application
    Filed: September 10, 2018
    Publication date: January 10, 2019
    Applicant: CITY OF HOPE
    Inventors: Yun YEN, Qiang LIU, Fouad KANDEEL, Kevin FERRERI, Steve S. SOMMER, Rasha SHEHATTA
  • Ultra-high sensitive monitoring of early transplantation failure
    Patent number: 10072294
    Abstract: The present invention provides a method for detecting transplantation failure of a transplanted organ or cells which comprises detecting a donor-positive but recipient-negative DNA marker in the recipient's plasma using pyrophosphorolysis activated polymerization. Because of the high sensitivity, specificity and selectivity of pyrophosphorolysis activated polymerization, transplantation failure can be detected at early stages and treatment can be initiate earlier.
    Type: Grant
    Filed: February 16, 2012
    Date of Patent: September 11, 2018
    Assignee: CITY OF HOPE
    Inventors: Yun Yen, Qiang Liu, Fouad Kandeel, Kevin Ferreri, Steve S. Sommer, Rasha Shehatta
  • Methods, compositions, and kits for improving pancreatic beta cell viability and treating diseases or conditions related to beta cell destruction
    Patent number: 10022403
    Abstract: The present disclosure provides novel methods for increasing ?-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase ?-cell viability.
    Type: Grant
    Filed: March 16, 2015
    Date of Patent: July 17, 2018
    Assignee: CITY OF HOPE
    Inventors: Sanjay Awasthi, Sushma Yadav, Ismail Al Abdullah, Fouad Kandeel, Brian McFadden, Indu Nair, Sharad S. Singhal
  • METHODS, COMPOSITIONS, AND KITS FOR IMPROVING PANCREATIC BETA CELL VIABILITY AND TREATING DISEASES OR CONDITIONS RELATED TO BETA CELL DESTRUCTION
    Publication number: 20160151423
    Abstract: The present disclosure provides novel methods for increasing ?-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase ?-cell viability.
    Type: Application
    Filed: March 16, 2015
    Publication date: June 2, 2016
    Inventors: Sanjay AWASTHI, Sushma YADAV, Ismail AL ABDULLAH, Fouad KANDEEL, Brian MCFADDEN, Indu NAIR, Sharad S. SINGHAL
  • ULTRA-HIGH SENSITIVE MONITORING OF EARLY TRANSPLANTATION FAILURE
    Publication number: 20150126373
    Abstract: The present invention provides a method for detecting transplantation failure of a transplanted organ or cells which comprises detecting a donor-positive but recipient-negative DNA marker in the recipient's plasma using pyrophosphorolysis activated polymerization. Because of the high sensitivity, specificity and selectivity of pyrophosphorolysis activated polymerization, transplantation failure can be detected at early stages and treatment can be initiate earlier.
    Type: Application
    Filed: February 16, 2012
    Publication date: May 7, 2015
    Applicant: CITY OF HOPE
    Inventors: Yun Yen, Qiang Liu, Fouad Kandeel, Kevin Ferreri, Steve S. Sommer, Rasha Shehatta
  • CARBOHYDRATE MODELING METHODS, SYSTEMS, AND DEVICES
    Publication number: 20130317316
    Abstract: The present application provides novel methods and devices for carbohydrate monitoring and diabetes treatment.
    Type: Application
    Filed: May 28, 2013
    Publication date: November 28, 2013
    Inventor: Fouad KANDEEL